MX2024011062A - Vacuna viva contra mycoplasma synoviae. - Google Patents

Vacuna viva contra mycoplasma synoviae.

Info

Publication number
MX2024011062A
MX2024011062A MX2024011062A MX2024011062A MX2024011062A MX 2024011062 A MX2024011062 A MX 2024011062A MX 2024011062 A MX2024011062 A MX 2024011062A MX 2024011062 A MX2024011062 A MX 2024011062A MX 2024011062 A MX2024011062 A MX 2024011062A
Authority
MX
Mexico
Prior art keywords
mycoplasma synoviae
vaccine
live mycoplasma
birds
synoviae vaccine
Prior art date
Application number
MX2024011062A
Other languages
English (en)
Spanish (es)
Inventor
Naola M Ferguson-Noel
Original Assignee
Univ Georgia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgia filed Critical Univ Georgia
Publication of MX2024011062A publication Critical patent/MX2024011062A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2024011062A 2022-03-14 2023-03-13 Vacuna viva contra mycoplasma synoviae. MX2024011062A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263319532P 2022-03-14 2022-03-14
PCT/US2023/015103 WO2023177620A1 (en) 2022-03-14 2023-03-13 Live mycoplasma synoviae vaccine

Publications (1)

Publication Number Publication Date
MX2024011062A true MX2024011062A (es) 2024-09-23

Family

ID=88024180

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011062A MX2024011062A (es) 2022-03-14 2023-03-13 Vacuna viva contra mycoplasma synoviae.

Country Status (8)

Country Link
US (1) US20250186512A1 (https=)
EP (1) EP4493202A1 (https=)
JP (1) JP2025509627A (https=)
CN (1) CN118891358A (https=)
AR (1) AR128777A1 (https=)
AU (1) AU2023235062A1 (https=)
MX (1) MX2024011062A (https=)
WO (1) WO2023177620A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9710606B (en) * 1996-12-05 1998-06-12 Akzo Nobel Nv Non-virulent Mycoplasma synoviae vaccine thereof.
EP3391903B1 (en) * 2017-04-21 2022-02-23 The Pirbright Institute Recombinant gallid herpesvirus 3 vaccines encoding heterologous avian pathogen antigens
CN112779193B (zh) * 2021-02-24 2022-09-27 福建省农业科学院畜牧兽医研究所 一株滑液囊支原体强毒株及其应用

Also Published As

Publication number Publication date
US20250186512A1 (en) 2025-06-12
WO2023177620A9 (en) 2024-05-10
JP2025509627A (ja) 2025-04-11
CN118891358A (zh) 2024-11-01
EP4493202A1 (en) 2025-01-22
AU2023235062A1 (en) 2024-09-19
WO2023177620A1 (en) 2023-09-21
AR128777A1 (es) 2024-06-12

Similar Documents

Publication Publication Date Title
MX2010005014A (es) Vacuna viva avirulenta de mycoplasma hyopneumoniae con adyuvante.
MX2024006606A (es) Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos.
WO2021226436A8 (en) Optimized nucleotide sequences encoding sars-cov-2 antigens
JP2019517828A5 (https=)
MY182282A (en) Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
PH12019500672A1 (en) Multivalent pneumococcal vaccine compositions comprising polysachharide-protein conjugates
NZ595914A (en) Vaccines comprising attenuated mycoplasma bovis strains and method for the attenuation
MX2021014948A (es) Metodos de tratamiento de pacientes con una composicion inmunogenica que protege contra el seroripo 29 de s. pneumoniae.
Patil et al. Virulence pattern of Avibacterium paragallinarum isolates studied from Indian field condition
Lanckriet et al. Variable protection after vaccination of broiler chickens against necrotic enteritis using supernatants of different Clostridium perfringens strains
MX2020006662A (es) Vacuna combinada intradermica contra mycoplasma y circovirus porcino.
WO2023004415A3 (en) Sars-cov-2 vaccine using bacterial spores expressing antigenic fragments
MX2023003198A (es) Aislado atenuado de la cepa delmarva/1639 (dmv1639) de virus de la bronquitis infecciosa.
MX2024011062A (es) Vacuna viva contra mycoplasma synoviae.
Castilla et al. Distribution of virulence genes sefC, pefA and spvC in Salmonella Enteritidis phage type 4 strains isolated in Brazil
MX2022006546A (es) Reovirus aviar atenuado cepas 94826 c140 y 96139 c140.
EP4233912A3 (en) Compositions for use as a prophylactic agent to those at risk of infection of tuberculosis, or as secondary agents for treating infected tuberculosis patients
BR0312640A (pt) Formulação contra mycoplasma gallisepticum
CA2222482A1 (en) Non-virulent mycoplasma synoviae and vaccine thereof
FI3334454T3 (fi) Mycoplasma bovis -koostumuksia
WO2023092023A3 (en) Methods of preventing, treating, or reducing the severity of coronavirus disease 2019 (covid-19)
MX2023010693A (es) Metodo y composicion de una vacuna para enfermedades bacterianas en invertebrados.
RU2017110230A (ru) Вакцина для производства продукции животноводства
JP2017525726A5 (https=)
KR101615186B1 (ko) 결핵 백신의 면역효과 증강용 조성물 및 면역효과 증진 방법